At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Sequential SGN-35 Therapy With Adriamycin, Vinblastine, and Dacarbazine (S-AVD) for Older Patients With Untreated Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin, doxorubicin hydrochloride, and 10 other interventions for Adult Lymphocyte Depletion Hodgkin Lymphoma and 6 related conditions. Completed, enrolled 49 participants across 7 sites.
Detailed Summary
This phase II trial studies how well giving brentuximab vedotin together with combination chemotherapy works in treating older patients with previously untreated stage II-IV Hodgkin lymphoma (HL). Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine, and dacarbazine (AVD), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin, doxorubicin hydrochloride, vinblastine, and dacarbazine together may kill more cancer cells.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Ancillary studies
Optional correlative studies
Optional correlative studies
Correlative studies
Correlative studies
Optional correlative studies
Optional correlative studies
Optional correlative studies